Navigation Links
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
Date:3/24/2010

Monthly dialogues replace annual reviews to give employees more ‘real time’ feedback. Employee development is a priority at Merrimack, which has hired 50 people since October 2009 and is a recipient of a $1.5 million Massachusetts Life Sciences Center tax incentive award for job creation.

Cambridge, Mass (PRWEB) March 24, 2010 -- Merrimack Pharmaceuticals was one of 18 winners out of more than 100 entries in Human Resources magazine’s second annual competition for the most noteworthy HR ideas. Awards were in four categories: Benefits, HR Technology, Talent Management and Training & Development.

Merrimack was recognized in the Talent Management category for the company’s decision last year to replace its semi-annual review process with 12 monthly employee dialogue sessions. “Talking monthly helps ensure that managers are actively involved in their employees’ development and creates alignment around team and company objectives,”    said Andy Porter, senior director of Human Resources, at Merrimack. “As Merrimack continues to grow, it’s critically important that we have a strong foundation of manager-employee feedback in place.” The dialogues include: goal check-in, job competencies and development, one actionable item the employee can improve, and types of support the manager can provide.

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

###

Read the full story at http://www.prweb.com/releases/merrimackpharma/hraward/prweb3770804.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
2. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
3. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
7. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
11. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
(Date:6/22/2017)... ... 2017 , ... For the months of May and June, ... series on “Cell Therapy Regulation” for its regenerative medicine followship. The ... regulatory challenges of stem cell medical research. , Stem cell clinical trials present ...
(Date:6/22/2017)... ... , ... Charm Sciences, Inc. is pleased to announce that its Charm Amphenicol ... as a screening test at dairies and farms for raw commingled cow milk. The ... EZ Lite system. These systems are a combination incubator and reader in one. , ...
(Date:6/20/2017)...  Kibow Biotech Inc., a pioneer in developing "Enteric ... a new patent covering a unique method for preventing ... and Trademark Office on May 23 rd 2017. ... Bio award in 2014 in San Diego, ... to chronic disease. Renadyl™, the first and only dietary ...
(Date:6/19/2017)... ... 2017 , ... As Vice President, Product Services, Mr. Guinter ... support, and client process and SOP development. , Mr. Guinter brings a wealth ... for service providers and top-tier pharmaceuticals, and as an independent consultant supported a ...
Breaking Biology Technology:
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Biology News(10 mins):